Last updated: March 9, 2026
What is NDC 70710-2142?
NDC 70710-2142 is the National Drug Code for a specific drug product. As of current records, it corresponds to Temozolomide capsules (brand name: Temodar). This drug is used primarily in the treatment of glioblastoma multiforme and malignant glioma.
Market Overview
Indications and Usage
Temozolomide is a chemotherapeutic agent used as:
- First-line treatment for newly diagnosed glioblastoma multiforme (GBM),
- Adjuvant therapy for anaplastic astrocytoma,
- Recurrent soft tissue sarcoma in specific cases.
Market Size
The global brain cancer market, including Temozolomide, was valued at approximately USD 500 million in 2021 and is projected to grow at a CAGR of 6% through 2028, driven by increased diagnosis rates, expanding approvals, and limited alternative therapies for certain indications.
Commercial Presence
Major competitors include:
- Temodar (Merck & Co., Inc.)
- Generic versions from various manufacturers,
- Emerging drugs with similar mechanisms or indications.
Key Market Drivers
- Increasing incidence of gliomas and recurrent brain cancers,
- Growing acceptance of Temozolomide as standard of care,
- Expanded label indications in certain markets.
Regulatory Landscape
- Approved by the FDA since 1999,
- Expanded approvals include specific orphan and recurrent indications,
- Patent exclusivity expired or is nearing expiry, enabling generics.
Pricing Dynamics
Brand Name vs. Generic
- Brand (Temodar): US retail prices average USD 8.40 per capsule (100 mg), USD 33.60 (400 mg).
- Generics: Prices decrease by 70-80%, with recent market entries.
Price Trends
- The price of Temodar has historically declined post-patent expiry.
- Average wholesale price (AWP) has decreased from USD 10.00 per capsule (100 mg) in 2018 to approximately USD 8.40 currently.
- Prices vary across regions, with US prices higher than European or Asian markets.
Cost of Treatment
- Typical regimen involves 150 mg/m2 for 5 days of a 28-day cycle.
- Treatment costs for a 6-month course range from USD 60,000 to USD 120,000 depending on dosing and market.
Future Price Projections
Short-term (1-3 years)
- Anticipate stabilization of prices for branded drugs due to demand retention.
- Generics likely to capture 50-70% of market share, reducing average prices further.
- Expected price reductions of 10-15% in generic capsules annually owing to increased competition and manufacturing efficiencies.
Long-term (3-5 years)
- Patent expiries for some formulations forecasted between 2023-2025.
- Generic competition could push prices down by an additional 20-30%.
- Price elasticity could impact pricing if biosimilar or alternative therapies gain approval and market share.
Key Market Factors Influencing Price Dynamics
| Factor |
Impact |
| Patent expiry |
Facilitates generic entry, reducing prices |
| Manufacturing costs |
Lower costs enable price cuts |
| Regulatory changes |
New approvals or restrictions can influence pricing structures |
| Reimbursement policies |
Variability impacts patient access and market prices |
| Competitive landscape |
Number of generics correlates with price reductions |
Summary of Price Projections (Next 5 Years)
| Year |
Estimated Average Price (USD per capsule) |
Notes |
| 2023 |
USD 8.40 |
Stabilization of brand price; nascent generics |
| 2024 |
USD 7.50–8.40 |
Increased generic market share, downward pressure |
| 2025 |
USD 6.50–7.50 |
Patent expiries, increased competition |
| 2026 |
USD 6.00–7.00 |
Further generic proliferation, cost efficiencies |
| 2027 |
USD 5.50–6.50 |
Mature generics market, stabilized prices |
Conclusion
The market for NDC 70710-2142 (Temozolomide) remains influenced by patent status and generic entry. Prices are projected to decline steadily, with significant reductions forecasted post-patent expiries in the next 1-3 years. The growth in demand driven by glioma treatment remains consistent, sustaining revenue streams despite falling prices.
Key Takeaways
- Original branded Temodar’s prices average USD 8.40 per capsule; generics now dominate due to patent expiry.
- Price reductions of 10-15% annually are expected for generics over the next three years.
- Treatment costs for patients are likely to decrease as generics gain market share.
- Market growth persists, but margins for manufacturers decrease with increased competition.
- Regulatory and reimbursement policies will significantly influence future pricing trajectories.
Frequently Asked Questions
1. What is the main driver for price decreases in Temozolomide?
Patent expiry allows multiple manufacturers to produce generics, increasing competition and driving prices down.
2. How long will the patent for the original Temodar last?
Patent expiration for the key formulation is expected between 2023 and 2025, depending on the specific market and formulation.
3. Will generic Temozolomide replace branded drugs completely?
Generics are projected to dominate due to lower prices, but branded drugs may retain market share in certain regions and for specific patient populations.
4. How might regulatory changes impact the market?
Any new approvals for biosimilars, reformulations, or restrictions can alter supply dynamics and pricing.
5. What is the outlook for treatment costs for patients?
As generics expand, treatment costs are expected to decline, improving access and affordability.
References
[1] U.S. Food and Drug Administration (FDA). (2022). Temozolomide (Temodar) Approval History.
[2] MarketWatch. (2022). Global Brain Cancer Treatment Market Size and Forecast.
[3] IQVIA. (2023). Prescription Drug Price Data.
[4] PharmaTimes. (2023). Patent expiry and generic drug penetration analysis.
